Covalent launches new macular health eye vitamin
Covalent Medical has announced the manufacturing and distribution of a new macular health eye vitamin called Focus MaculaPro.
Focus MaculaPro is manufactured in a facility registered by the Food and Drug Administration and laboratory tested to assure quality and safety, the company said.
Additionally, Focus MaculaPro is based on the formula used in the AREDS eye vitamin study.
Covalent Medical doctors believe that by working together as a group to produce a high-quality, science-based, affordable macular health vitamin like Focus MaculaPro they can improve compliance, promote eye health.
Related Insight
Suppliers Directory
Euroscreen - Your Drug Discovery Partner
Euroscreen is a private, Belgian, preclinical-stage, drug discovery and development company targeting G Protein Coupled Receptors (GPCRs) to provide first-in-class small molecule drug candidates for the therapeutic area of metabolism, inflammation and women's health.
Production & Manufacturing > Manufacturing > Suppliers
Pharma IQ - Workshops, Conferences and Training Courses for Pharmaceutical Professionals
Pharma IQ, a division of IQPC, provides a forum to address the critical issues facing the Pharmaceutical Industry today. Pharma IQ utilises workshop, conference and training course formats to facilitate a learning environment for pharmaceutical professionals working in all areas of drug development: from Discovery to Post-Marketing.
Production & Manufacturing > Manufacturing > Suppliers
Enzo Life Sciences - Cell Analysis, Molecular Biology, Drug Development and Proteostasis
Enzo has been providing enabling technologies for the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies for over 30 years.
Production & Manufacturing > Manufacturing > Suppliers
Air Products - Worry-Free Gas Supply and Solutions
With a 99.95% on-time delivery record, excellent medical gas compliance and safety performance, and a total solutions approach to doing business, Air Products provides worry-free supply of nitrogen, hydrogen, oxygen, and other gases. We also provide technical support for a range of pharmaceutical and biological applications that include fermentation, hydrogenation, inerting and reaction cooling.
Production & Manufacturing > Manufacturing > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Manufacturing Intelligence
Worry-Free Gas Supply and Solutions for the Pharmaceutical Industry
Published by Air Products
Production & Manufacturing > Manufacturing > White Papers
Five Keys to Reducing Time-to-Market
Published by Vetter Pharma International
Production & Manufacturing > Manufacturing > White Papers
Highly Potent Active Pharmaceutical Ingredients
Published by Heraeus
Production & Manufacturing > Manufacturing > White Papers
PMPS
Published by Softbox
Production & Manufacturing > Manufacturing > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.